Progesterone_NN receptors_NNS -_: animal_JJ models_NNS and_CC cell_NN signaling_VBG in_IN breast_NN cancer_NN :_: Expression_NN and_CC transcriptional_JJ activity_NN of_IN progesterone_NN receptor_NN A_DT and_CC progesterone_NN receptor_NN B_NN in_IN mammalian_JJ cells_NNS Abstract_NP |_SYM Progesterone_NN is_VBZ an_DT essential_JJ regulator_NN of_IN normal_JJ female_JJ reproductive_JJ function_NN ._SENT Its_PP$ effects_NNS are_VBP mediated_VBN by_IN two_CD nuclear_JJ progesterone_NN receptor_NN (_( PR_NP )_) proteins_NNS ,_, PRA_NP and_CC PRB_NP ,_, which_WDT are_VBP identical_JJ except_IN for_IN an_DT additional_JJ 164_CD amino_NN acids_NNS at_IN the_DT N-terminal_JJ end_NN of_IN PRB_NP ._SENT Transcriptional_JJ analyses_NNS of_IN the_DT two_CD receptor_NN forms_NNS have_VBP assigned_VBN strikingly_RB distinct_JJ functional_JJ signatures_NNS to_TO the_DT two_CD PRs_NN ,_, despite_IN their_PP$ apparent_JJ physical_JJ similarity_NN ._SENT The_DT basis_NN of_IN these_DT differences_NNS is_VBZ yet_RB to_TO be_VB fully_RB understood_VBN ._SENT Furthermore_RB ,_, these_DT differences_NNS are_VBP strongly_RB influenced_VBN by_IN the_DT cell_NN type_NN and_CC the_DT promoter_NN used_VBD ._SENT We_PP review_VBP the_DT mammalian_JJ transcriptional_JJ studies_NNS of_IN PRA_NP and_CC PRB_NP ,_, and_CC compare_VB them_PP with_IN what_WP is_VBZ known_VBN about_IN their_PP$ expression_NN and_CC function_NN in_IN target_NN tissues_NNS ._SENT progesterone_NN receptor_NN ,_, progestin_NN signaling_VBG ,_, transcriptional_JJ activation_NN ,_, Progesterone_NP plays_VBZ a_DT pivotal_JJ role_NN in_IN normal_JJ female_JJ reproduction_NN ,_, in_IN the_DT uterus_NN ,_, the_DT ovary_NN ,_, the_DT mammary_JJ gland_NN and_CC the_DT brain_NN ._SENT The_DT number_NN of_IN cellular_JJ pathways_NNS regulated_VBN by_IN progesterone_NN reflects_VBZ the_DT complexity_NN of_IN its_PP$ physiological_JJ role_NN ._SENT In_IN normal_JJ breast_NN development_NN ,_, progesterone_NN directs_VBZ the_DT formation_NN of_IN lobular-alveolar_JJ structures_NNS and_CC also_RB affects_VBZ differentiation_NN in_IN the_DT breast_NN by_IN modulation_NN of_IN milk_NN protein_NN synthesis_NN ._SENT In_IN the_DT human_JJ endometrium_NN ,_, progesterone_NN directs_VBZ glandular_JJ differentiation_NN and_CC glycogenesis_NN ,_, as_RB well_RB as_IN stromal_JJ proliferation_NN and_CC development_NN of_IN predecidual_JJ cells_NNS ._SENT These_DT effects_NNS are_VBP mediated_VBN through_IN the_DT nuclear_JJ progesterone_NN receptor_NN (_( PR_NP )_) ,_, expressed_VBN as_IN two_CD protein_NN forms_NNS (_( PRA_NP and_CC PRB_NP )_) ._SENT There_EX is_VBZ increasing_VBG evidence_NN to_TO date_VB that_IN PRA_NP and_CC PRB_NP are_VBP functionally_RB different_JJ ,_, and_CC that_IN it_PP is_VBZ the_DT balance_NN between_IN these_DT two_CD forms_NNS that_WDT may_MD make_VB it_PP possible_JJ for_IN progesterone_NN to_TO affect_VB such_JJ diverse_JJ physiological_JJ targets_NNS ._SENT Much_RB of_IN this_DT evidence_NN is_VBZ conflicting_JJ and_CC model_JJ specific_NN ,_, however_RB ,_, and_CC the_DT true_JJ differences_NNS between_IN the_DT receptor_NN forms_NNS in_IN normal_JJ tissues_NNS are_VBP yet_RB to_TO be_VB fully_RB understood_VBN ._SENT The_DT purpose_NN of_IN the_DT present_JJ article_NN is_VBZ to_TO review_VB the_DT current_JJ state_NN of_IN knowledge_NN about_IN the_DT transcriptional_JJ differences_NNS between_IN PRA_NP and_CC PRB_NP from_IN mammalian_NN in_IN vitro_NN models_NNS ,_, and_CC to_TO correlate_VB this_DT with_IN the_DT effects_NNS of_IN altered_JJ PRA_NP and_CC PRB_NP levels_NNS on_IN target_NN tissues_NNS ._SENT The_DT PR_NP is_VBZ a_DT member_NN of_IN a_DT large_JJ family_NN of_IN ligand-activated_JJ nuclear_JJ transcription_NN regulators_NNS ,_, which_WDT are_VBP characterised_VBN by_IN organisation_NN into_IN specific_JJ functional_JJ domains_NNS and_CC are_VBP conserved_VBN ,_, to_TO differing_VBG degrees_NNS ,_, between_IN species_NNS and_CC family_NN members_NNS ._SENT The_DT PR_NP is_VBZ made_VBN up_RP of_IN a_DT central_JJ DNA_NN binding_VBG domain_NN and_CC a_DT carboxyl-terminal_JJ ligand-binding_NN domain_NN ._SENT In_IN addition_NN ,_, the_DT receptor_NN contains_VBZ multiple_JJ activation_NN function_NN (_( AF_NP )_) and_CC inhibitory_JJ function_NN elements_NNS ,_, which_WDT enhance_VBP and_CC repress_VBP transcriptional_JJ activation_NN of_IN the_DT PR_NP by_IN association_NN of_IN these_DT regions_NNS with_IN transcriptional_JJ coregulators_NNS ._SENT In_IN most_JJS species_NNS examined_VBD ,_, the_DT PR_NP exists_VBZ as_IN two_CD distinct_JJ forms_NNS (_( PRA_NP and_CC PRB_NP )_) ._SENT The_DT expression_NN of_IN human_JJ PR_NP is_VBZ controlled_VBN by_IN two_CD promoters_NNS ,_, which_WDT direct_VBP the_DT synthesis_NN of_IN two_CD distinct_JJ subgroups_NNS of_IN mRNA_NN transcripts_NNS encoding_VBG the_DT two_CD receptor_NN proteins_NNS ._SENT The_DT two_CD PR_NP forms_NNS are_VBP identical_JJ except_IN that_WDT PRA_NP lacks_VBZ 164_CD amino_NN acids_NNS contained_VBN at_IN the_DT N-terminal_JJ end_NN of_IN PRB_NP ._SENT The_DT region_NN of_IN the_DT protein_NN that_WDT is_VBZ unique_JJ to_TO PRB_NP contains_VBZ a_DT transcription_NN activation_NN function_NN ,_, AF3_NP ,_, in_IN addition_NN to_TO AF1_NP and_CC AF2_NP ,_, which_WDT are_VBP common_JJ to_TO PRA_NP ._SENT Newly_RB transcribed_VBN cytoplasmic_JJ PR_NP is_VBZ assembled_VBN in_IN an_DT inactive_JJ multiprotein_NN chaperone_NN complex_NN that_WDT dissociates_VBZ on_IN ligand_NN binding_NN and_CC receptor_NN activation_NN ._SENT Progestin_NN binding_VBG to_TO the_DT PR_NP causes_VBZ a_DT conformational_JJ change_NN and_CC dimerisation_NN ,_, resulting_VBG in_IN association_NN of_IN the_DT progestin-complexed_JJ PR_NP dimer_NN with_IN specific_JJ coactivators_NNS and_CC general_JJ transcription_NN factors_NNS ._SENT The_DT activated_VBN complex_JJ binds_NNS to_TO progestin_NN response_NN elements_NNS (_( PREs_NP )_) in_IN the_DT promoters_NNS of_IN target_NN genes_NNS ,_, resulting_VBG in_IN modulation_NN of_IN transcription_NN of_IN those_DT genes_NNS (_( reviewed_VBN in_IN )_) ._SENT There_EX is_VBZ now_RB considerable_JJ evidence_NN for_IN differences_NNS in_IN the_DT transcriptional_JJ activities_NNS of_IN PRA_NP and_CC PRB_NP from_IN transient_JJ cotransfection_NN into_IN a_DT variety_NN of_IN cell_NN lines_NNS of_IN PRA_NP and/or_CC PRB_NP and_CC reporter_NN constructs_NNS containing_VBG progestin-responsive_JJ sequences_NNS ._SENT These_DT constructs_NNS range_VBP from_IN the_DT simple_JJ PRE-tk-CAT_NN (_( containing_VBG one_CD copy_NN of_IN a_DT palindromic_JJ PRE_NN )_) to_TO more_JJR complex_JJ constructs_NNS such_JJ as_IN those_DT incorporating_VBG the_DT mouse_NN mammary_JJ tumor_NN virus_NN long_JJ terminal_NN repeat_NN ,_, which_WDT contains_VBZ multiple_JJ hormone-responsive_JJ elements_NNS ._SENT PRB_NP exhibits_VBZ hormone-dependent_JJ transactivation_NN in_IN all_DT cell_NN types_NNS examined_VBD irrespective_RB of_IN the_DT complexity_NN of_IN the_DT response_NN elements_NNS ,_, whereas_IN the_DT transcriptional_JJ activity_NN of_IN PRA_NP is_VBZ cell_NN specific_JJ and_CC reporter_NN specific_NN ._SENT With_IN reporter_NN constructs_NNS containing_VBG a_DT single_JJ palindromic_JJ PRE_NP ,_, PRA_NP displays_VBZ similar_JJ transactivation_NN activity_NN to_TO PRB_NP ._SENT However_RB ,_, this_DT activity_NN is_VBZ reduced_VBN or_CC inactive_JJ when_RB more_RBR complex_JJ response_NN elements_NNS such_JJ as_IN the_DT mouse_NN mammary_JJ tumor_NN virus_NN long_JJ terminal_NN repeat_NN and_CC PRE2TATAtk_NN constructs_NNS are_VBP used_VBN ._SENT Interestingly_RB ,_, PRA_NP acts_VBZ as_IN a_DT transdominant_JJ inhibitor_NN of_IN PRB_NN in_IN situations_NNS where_WRB PRA_NP has_VBZ little_RB or_CC no_DT transactivational_JJ activity_NN ._SENT Moreover_RB ,_, PRA_NP can_MD regulate_VB the_DT transcriptional_JJ activity_NN of_IN other_JJ nuclear_JJ receptors_NNS such_JJ as_IN glucocorticoid_NN ,_, mineralocorticoid_NN ,_, androgen_NN and_CC estrogen_NN ,_, suggesting_VBG that_IN PRA_NP may_MD play_VB a_DT central_JJ role_NN in_IN regulation_NN of_IN activity_NN of_IN a_DT number_NN of_IN nuclear_JJ receptors_NNS in_IN addition_NN to_TO PRB_NP ._SENT The_DT ability_NN of_IN PRA_NP to_TO act_VB as_IN a_DT transdominant_JJ repressor_NN is_VBZ highly_RB model_JJ specific_NN ,_, however_RB ,_, and_CC there_EX is_VBZ considerable_JJ variability_NN between_IN reports_NNS ._SENT McDonnell_NP and_CC Goldman_NP reported_VBD that_IN PRA_NP but_CC not_RB PRB_NP ,_, in_IN the_DT presence_NN of_IN either_DT progesterone_NN or_CC anti-progestins_NNS ,_, lessened_VBD the_DT ability_NN of_IN estrogen_NN to_TO induce_VB an_DT estrogen-responsive_JJ reporter_NN when_WRB the_DT two_CD constructs_NNS were_VBD transfected_VBN into_IN CV-1_NP or_CC HS578T_NP cells_NNS ,_, but_CC not_RB into_IN HepG2_JJ cells_NNS ._SENT PRA_NP had_VBD similar_JJ anti-estrogenic_JJ effects_NNS on_IN endogenous_JJ estrogen_NN receptor_NN activation_NN of_IN a_DT minimal_JJ estrogen-responsive_JJ reporter_NN in_IN MCF-7_JJ breast_NN cancer_NN cells_NNS in_IN the_DT presence_NN of_IN RU_NP 38486_CD ._SENT When_WRB the_DT estrogen-responsive_JJ region_NN of_IN the_DT pS2_JJ gene_NN was_VBD used_VBN as_IN a_DT reporter_NN in_IN MCF-7_JJ cells_NNS ,_, however_RB ,_, PRB_NP and_CC not_RB PRA_NP repressed_VBD activation_NN of_IN the_DT reporter_NN by_IN estrogen_NN ._SENT The_DT mechanisms_NNS by_IN which_WDT PRA_NP and_CC PRB_NP exert_VBP such_JJ apparently_RB different_JJ transcriptional_JJ activities_NNS in_IN various_JJ cell_NN and_CC promoter_NN systems_NNS remain_VBP largely_RB unknown_JJ ,_, although_IN a_DT number_NN of_IN possible_JJ scenarios_NNS have_VBP been_VBN proposed_VBN ._SENT The_DT physical_JJ differences_NNS at_IN the_DT N-terminal_JJ end_NN of_IN the_DT two_CD receptors_NNS are_VBP clearly_RB responsible_JJ for_IN some_DT transcriptional_JJ differences_NNS ._SENT In_IN addition_NN to_TO the_DT fact_NN that_IN AF3_NP is_VBZ unique_JJ to_TO PRB_NP ,_, the_DT PRB-specific_JJ region_NN has_VBZ a_DT distinct_JJ conformation_NN in_IN solution_NN and_CC is_VBZ likely_JJ to_TO mask_VB an_DT inhibitory_JJ domain_NN that_WDT is_VBZ active_JJ in_IN the_DT N-terminus_NP of_IN the_DT PRA_NP protein_NN ._SENT This_DT could_MD act_VB to_TO enhance_VB the_DT transcriptional_JJ activity_NN of_IN PRB_NP ,_, as_RB well_RB as_IN preventing_VBG it_PP from_IN acting_VBG as_IN an_DT inhibitor_NN of_IN other_JJ receptors_NNS ._SENT The_DT unique_JJ AF_NN in_IN PRB_NP may_MD confer_VB a_DT difference_NN in_IN affinities_NNS of_IN the_DT two_CD PRs_NN for_IN coregulators_NNS ._SENT When_WRB compared_VBN in_IN a_DT phage_NN display_NN assay_NN ,_, the_DT two_CD PR_NP forms_NNS bind_NN to_TO distinct_JJ subgroups_NNS of_IN peptides_NNS ._SENT This_DT suggests_VBZ that_IN coactivators_NNS may_MD bind_VB differently_RB to_TO the_DT two_CD PRs_NN or_CC that_IN the_DT two_CD receptors_NNS bind_NN to_TO different_JJ subgroups_NNS of_IN coactivators_NNS ._SENT Motifs_NNS contained_VBN in_IN AF3_NP ,_, with_IN the_DT same_JJ sequence_NN as_IN the_DT NR_NP boxes_NNS of_IN coactivators_NNS ,_, have_VBP been_VBN shown_VBN to_TO be_VB necessary_JJ for_IN the_DT transcriptional_JJ activity_NN of_IN the_DT PRB-unique_NP AF_NP and_CC may_MD form_VB contacts_NNS between_IN the_DT receptor_NN and_CC a_DT unique_JJ set_NN of_IN cofactors_NNS ,_, or_CC within_IN the_DT PR_NP dimer_NN itself_PP ._SENT Given_VBN that_IN the_DT PR_NP acts_NNS in_IN combination_NN with_IN multiple_JJ other_JJ transcription_NN factors_NNS to_TO affect_VB transcription_NN ,_, it_PP is_VBZ possible_JJ that_IN variability_NN of_IN the_DT tissue-specific_JJ expression_NN of_IN the_DT components_NNS of_IN this_DT multiprotein_NN complex_NN may_MD result_VB in_IN different_JJ PRA_NP and_CC PRB_NP activities_NNS in_IN the_DT same_JJ cell_NN ._SENT Furthermore_RB ,_, differential_JJ cofactor_NN requirements_NNS between_IN gene_NN promoters_NNS may_MD lead_VB to_TO differences_NNS in_IN the_DT transcriptional_JJ efficacy_NN of_IN the_DT two_CD PRs_NN on_IN the_DT same_JJ promoter_NN ._SENT Further_JJR evidence_NN is_VBZ required_VBN to_TO support_VB these_DT assertions_NNS since_RB ,_, although_IN most_JJS cofactors_NNS are_VBP expressed_VBN at_IN limiting_VBG levels_NNS ,_, they_PP have_VBP been_VBN demonstrated_VBN to_TO be_VB widely_RB expressed_VBN throughout_IN cell_NN types_NNS ._SENT Furthermore_RB ,_, a_DT degree_NN of_IN functional_JJ redundancy_NN in_IN PR_NP coactivators_NNS seems_VBZ to_TO exist_VB ,_, with_IN gene_NN knockout_NN studies_NNS of_IN SRC-1_NP delivering_VBG only_RB a_DT mild_JJ phenotype_NN and_CC the_DT demonstration_NN that_IN TIF2_NP and_CC SRC-1_NP are_VBP able_JJ to_TO activate_VB the_DT PR_NP to_TO a_DT similar_JJ extent_NN in_IN transfections_NNS ._SENT The_DT PR_NP regulates_VBZ the_DT expression_NN of_IN a_DT diverse_JJ population_NN of_IN transcriptional_JJ targets_NNS ,_, and_CC it_PP would_MD be_VB expected_VBN that_IN changes_NNS in_IN the_DT relative_JJ amounts_NNS of_IN PRA_NP and_CC PRB_NP would_MD result_VB in_IN altered_JJ target_NN gene_NN expression_NN patterns_NNS if_IN the_DT two_CD isoforms_NNS are_VBP transcriptionally_RB distinct_JJ ._SENT When_WRB patterns_NNS of_IN gene_NN regulation_NN were_VBD examined_VBN in_IN T47D_JJ breast_NN cancer_NN cells_NNS expressing_VBG exclusively_RB PRA_NP or_CC PRB_NP ,_, a_DT remarkably_RB small_JJ overlap_VBP was_VBD seen_VBN between_IN the_DT sets_NNS of_IN genes_NNS regulated_VBN by_IN the_DT two_CD receptors_NNS ,_, with_IN the_DT subset_NN of_IN genes_NNS regulated_VBN by_IN PRB_NP far_RB exceeding_VBG in_IN number_NN those_DT regulated_VBN by_IN PRA_NP ._SENT When_WRB the_DT relative_JJ expression_NN of_IN PRA_NP and_CC PRB_NP was_VBD varied_VBN in_IN wild-type_NN T47D_NN cells_NNS that_WDT already_RB express_VBP both_DT isoforms_NNS ,_, however_RB ,_, the_DT impact_NN on_IN transcription_NN was_VBD not_RB dramatic_JJ unless_IN PRA_NP was_VBD in_IN vast_JJ excess_NN over_IN PRB_NP ._SENT Furthermore_RB ,_, no_DT evidence_NN was_VBD seen_VBN of_IN dominant_JJ transcriptional_JJ inhibition_NN by_IN PRA_NP ._SENT These_DT data_NNS suggest_VBP that_IN coexpression_NN of_IN both_DT isoforms_NNS at_IN similar_JJ levels_NNS ,_, which_WDT is_VBZ common_JJ in_IN normal_JJ progesterone_NN target_NN cells_NNS (_( see_VB later_JJR )_) ,_, is_VBZ associated_VBN with_IN appropriate_JJ transcriptional_JJ response_NN to_TO progestins_NNS and_CC that_IN changes_NNS in_IN relative_JJ PRA_NP and_CC PRB_NP levels_NNS must_MD be_VB quite_RB dramatic_JJ before_IN physiological_JJ changes_NNS in_IN progestin_NN signaling_VBG are_VBP observed_VBN ._SENT In_IN general_NN ,_, PRA_NP and_CC PRB_NP are_VBP coexpressed_VBN in_IN the_DT same_JJ target_NN cells_NNS in_IN the_DT human_JJ ,_, and_CC their_PP$ relative_JJ expression_NN ,_, where_WRB it_PP has_VBZ been_VBN examined_VBN ,_, is_VBZ generally_RB close_JJ to_TO unity_NN ._SENT In_IN some_DT normal_JJ physiological_JJ circumstances_NNS ,_, and_CC in_IN some_DT cell_NN types_NNS ,_, there_EX is_VBZ a_DT predominance_NN of_IN one_CD isoform_NN ._SENT PRA_NP is_VBZ always_RB the_DT predominant_JJ isoform_NN in_IN the_DT uterine_JJ stroma_NN ,_, and_CC PRB_NP is_VBZ predominantly_RB expressed_VBN in_IN the_DT epithelial_JJ glands_NNS in_IN the_DT mid-secretory_JJ phase_NN of_IN the_DT menstrual_JJ cycle_NN ._SENT PRA_NP is_VBZ the_DT predominant_JJ isoform_NN in_IN the_DT rodent_NN and_CC is_VBZ widely_RB expressed_VBN in_IN the_DT macaque_NN reproductive_JJ system_NN ._SENT Predominance_NN of_IN one_CD isoform_NN also_RB occurs_VBZ in_IN cancers_NNS ._SENT In_IN breast_NN cancers_NNS ,_, the_DT equivalent_JJ expression_NN of_IN PRA_NP and_CC PRB_NP seen_VBN in_IN normal_JJ cells_NNS is_VBZ disrupted_VBN early_RB in_IN carcinogenesis_NN ,_, and_CC predominance_NN of_IN one_CD isoform_NN is_VBZ common_JJ ._SENT Most_RBS endometrial_JJ cancers_NNS express_VBP only_RB one_CD PR_NP isoform_NN ,_, and_CC isoform_NN predominance_NN is_VBZ associated_VBN with_IN higher_JJR histological_JJ grade_NN ._SENT The_DT association_NN of_IN PR_NP isoform_NN predominance_NN with_IN cancer_NN is_VBZ supported_VBN by_IN the_DT demonstration_NN that_IN transgenic_JJ mice_NNS overexpressing_VBG PRA_NP exhibited_VBN features_NNS in_IN their_PP$ mammary_JJ glands_NNS that_WDT were_VBD abnormal_JJ and_CC commonly_RB associated_VBN with_IN neoplasia_NN ._SENT The_DT expression_NN of_IN PRA_NP and_CC PRB_NP in_IN vivo_JJ supports_NNS a_DT role_NN for_IN both_DT isoforms_NNS in_IN normal_JJ physiology_NN ,_, particularly_RB in_IN the_DT human_JJ breast_NN ._SENT The_DT fact_NN that_IN the_DT equivalent_JJ levels_NNS of_IN the_DT two_CD proteins_NNS seen_VBN in_IN the_DT normal_JJ breast_NN become_VBN disrupted_VBD early_RB in_IN breast_NN carcinogenesis_NN ,_, and_CC that_DT predominance_NN of_IN one_CD PR_NP isoform_NN ,_, usually_RB PRA_NP ,_, is_VBZ seen_VBN in_IN cancers_NNS ,_, suggests_VBZ that_IN disrupted_VBN progesterone_NN signaling_VBG may_MD play_VB a_DT role_NN in_IN development_NN or_CC progression_NN of_IN breast_NN cancer_NN ._SENT In_IN addition_NN to_TO the_DT ligand-activated_JJ transcriptional_JJ effects_NNS already_RB discussed_VBN ,_, which_WDT reflect_VBP the_DT nuclear_JJ activity_NN of_IN this_DT receptor_NN ,_, the_DT PR_NP also_RB regulates_VBZ transcription_NN via_IN alternative_JJ pathways_NNS ._SENT Ligand-independent_JJ activation_NN of_IN the_DT PR_NP can_MD occur_VB and_CC provides_VBZ evidence_NN for_IN regulation_NN of_IN the_DT PR_NP via_IN membrane-generated_JJ signals_NNS ._SENT The_DT PR_NP also_RB interacts_VBZ with_IN cytoplasmic_JJ signaling_VBG pathways_NNS to_TO activate_VB c-Src_NP family_NN members_NNS ,_, and_CC PR_NP interactions_NNS with_IN the_DT mitogen-activated_JJ protein_NN kinase_NN pathway_NN are_VBP also_RB described_VBN ._SENT Migliaccio_NP et_FW al._FW found_VBD that_IN PR_NP activation_NN of_IN signaling_VBG pathways_NNS was_VBD independent_JJ of_IN the_DT transcriptional_JJ activity_NN of_IN the_DT receptor_NN and_CC was_VBD indirectly_RB mediated_VBN by_IN PRB_NP ,_, but_CC not_RB PRA_NP ,_, through_IN interaction_NN with_IN the_DT estrogen_NN receptor_NN ._SENT Other_JJ studies_NNS have_VBP examined_VBN the_DT ability_NN of_IN the_DT PR_NP to_TO transiently_RB activate_VB mitogen-activated_JJ protein_NN kinase_NN pathways_NNS but_CC have_VBP generally_RB focused_VBN on_IN PRB_NP ,_, which_WDT was_VBD more_JJR transcriptionally_RB active_JJ than_IN PRA_NP in_IN most_JJS settings_NNS (_( CA_NP Lange_NP ,_, personal_JJ communication_NN )_) ._SENT The_DT in_IN vitro_NN data_NNS on_IN the_DT relative_JJ activities_NNS of_IN PRA_NP and_CC PRB_NP tend_VBP to_TO support_VB the_DT view_NN that_IN PRB_NP is_VBZ the_DT active_JJ PR_NP ,_, whereas_IN PRA_NP is_VBZ either_RB inactive_JJ or_CC acts_VBZ as_IN an_DT inhibitor_NN of_IN PRB_NN activity_NN ._SENT However_RB ,_, this_DT perspective_NN is_VBZ at_IN odds_NNS with_IN the_DT demonstrated_VBN coexpression_NN of_IN both_DT isoforms_NNS in_IN normal_JJ physiology_NN and_CC with_IN the_DT distinct_JJ roles_NNS ascribed_VBN to_TO each_DT protein_NN from_IN knockout_JJ studies_NNS discussed_VBN in_IN the_DT other_JJ sections_NNS of_IN this_DT review_NN series_NN ._SENT An_DT explanation_NN for_IN the_DT discrepancy_NN between_IN the_DT in_IN vivo_JJ and_CC the_DT in_IN vitro_NN data_NNS resides_VBZ in_IN the_DT experimental_JJ protocols_NNS used_VBN to_TO examine_VB the_DT question_NN of_IN relative_JJ PRA_NP and_CC PRB_NP transcriptional_JJ activity_NN ._SENT Most_JJS of_IN the_DT information_NN has_VBZ been_VBN obtained_VBN from_IN transient_JJ transfection_NN studies_NNS largely_RB in_IN cell_NN lines_NNS that_WDT are_VBP not_RB progestin_NN targets_NNS ,_, using_VBG exogenously_RB transfected_JJ reporter_NN sequences_NNS and_CC each_DT isoform_NN in_IN isolation_NN ._SENT The_DT relative_JJ levels_NNS of_IN isoform_NN protein_NN coexpressed_VBN under_IN these_DT conditions_NNS cannot_MD be_VB known_VBN ,_, and_CC is_VBZ probably_RB highly_RB relevant_JJ to_TO interpretation_NN of_IN the_DT data_NNS ._SENT There_EX is_VBZ little_JJ evidence_NN in_IN vivo_JJ that_IN PRA_NP is_VBZ a_DT dominant_JJ inhibitor_NN of_IN PRB_NP ._SENT Moreover_RB ,_, when_WRB the_DT data_NNS in_IN human_JJ tissues_NNS and_CC null_JJ animals_NNS are_VBP taken_VBN together_RB ,_, they_PP suggest_VBP that_IN the_DT two_CD isoforms_NNS either_DT work_NN cooperatively_RB to_TO mediate_VB progesterone_NN action_NN or_CC suggest_VBP that_IN each_DT isoform_NN has_VBZ distinct_JJ physiological_JJ roles_NNS that_WDT are_VBP probably_RB cell_NN specific_NN and_CC promoter_NN specific_NN ._SENT A_DT combination_NN of_IN cooperative_JJ action_NN and_CC distinct_JJ activity_NN is_VBZ probably_RB the_DT best_JJS explanation_NN for_IN the_DT complex_JJ and_CC divergent_JJ pathways_NNS of_IN progesterone_NN action_NN in_IN normal_JJ and_CC malignant_JJ physiology_NN ._SENT AF_NN =_SYM activation_NN function_NN ;_: PR_NP =_SYM progesterone_NN receptor_NN ;_: PRE_NP =_SYM progestin_NN response_NN element_NN ._SENT 